journal
MENU ▼
Read by QxMD icon Read
search

Oncology

journal
https://www.readbyqxmd.com/read/29151109/reporting-of-randomized-trials-in-common-cancers-in-the-lay-media
#1
Domen Ribnikar, Hadar Goldvaser, Alberto Ocana, Arnoud J Templeton, Bostjan Seruga, Eitan Amir
BACKGROUND: Limited data exist about the role of the lay media in the dissemination of results of randomized controlled trials (RCTs) in common cancers. METHODS: Completed phase III RCTs evaluating new drugs in common cancers between January 2005 and October 2016 were identified from ClinicalTrials.gov. Lay media reporting was identified by searching LexisNexis Academic. Scientific reporting was defined as presentation at an academic conference or publication in full...
November 18, 2017: Oncology
https://www.readbyqxmd.com/read/29151106/survival-outcome-of-intermediate-grade-salivary-gland-carcinoma
#2
Gi Cheol Park, Jong-Lyel Roh, Kyung-Ja Cho, Yong Gi Jung, Hyoun Wook Lee, Tae Gyu Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
OBJECTIVE: Histological grade is the most important factor for defining treatment strategies and predicting prognosis for salivary gland carcinoma (SGC). We examined factors affecting long-term recurrence and survival among intermediate-grade SGC (IGSGC) patients to define optimal treatment modalities and outcomes. METHODS: We reviewed the clinical and pathological data on 108 IGSGC patients who underwent definitive surgery with or without postoperative radiotherapy...
November 18, 2017: Oncology
https://www.readbyqxmd.com/read/29151104/clinical-efficacy-and-safety-of-first-line-dasatinib-therapy-and-the-relevance-of-velocity-of-bcr-abl1-transcript-decline-for-achievement-of-molecular-responses-in-newly-diagnosed-chronic-phase-chronic-myeloid-leukemia-report-from-the-juntendo-yamanashi-cooperative
#3
Tomoiku Takaku, Noriyoshi Iriyama, Toru Mitsumori, Eriko Sato, Akihiko Gotoh, Keita Kirito, Masaaki Noguchi, Michiaki Koike, Junichi Sakamoto, Koji Oba, Norio Komatsu
OBJECTIVE: The use of tyrosine kinase inhibitors led to an improvement in the prognoses of patients with chronic myeloid leukemia (CML). The aims of this study were to investigate the efficacy and safety of dasatinib in Japanese patients and to explore the factors that affect the achievement of molecular responses. METHODS: The primary endpoint was a major molecular response (MMR) by 12 months. The halving time for BCR-ABL1 transcripts was calculated using transcript levels...
November 18, 2017: Oncology
https://www.readbyqxmd.com/read/29145211/patient-reported-outcome-results-from-the-open-label-randomized-phase-iii-select-bc-trial-evaluating-first-line-s-1-therapy-for-metastatic-breast-cancer
#4
Takuya Kawahara, Kojiro Shimozuma, Takeru Shiroiwa, Yasuhiro Hagiwara, Yukari Uemura, Takanori Watanabe, Naruto Taira, Takashi Fukuda, Yasuo Ohashi, Hirofumi Mukai
OBJECTIVE: To evaluate the effects of S-1, an orally administered 5-FU agent, versus taxane on patient-reported outcomes (PROs) in the SELECT BC trial. METHODS: Patients with HER2-negative and endocrine treatment-resistant breast cancer with metastasis or recurrence after surgery were randomly assigned to receive first-line taxane or S-1. PROs (secondary endpoint) were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Patient Neurotoxicity Questionnaire (PNQ) at baseline and at 3, 6, and 12 months...
November 17, 2017: Oncology
https://www.readbyqxmd.com/read/29136624/value-of-intraoperative-cytological-and-pathological-sentinel-lymph-node-diagnosis-in-fertility-sparing-trachelectomy-for-early-stage-cervical-cancer
#5
Kenzo Sonoda, Hideaki Yahata, Kaoru Okugawa, Eisuke Kaneki, Tatsuhiro Ohgami, Masafumi Yasunaga, Shingo Baba, Yoshinao Oda, Hiroshi Honda, Kiyoko Kato
BACKGROUND AND OBJECTIVES: Trachelectomy, a fertility-sparing surgery for early-stage cervical cancer, can be performed only when there is no extrauterine extension present. Therefore, identifying the sentinel lymph nodes (SLNs) and using them to obtain an intraoperative pathologic diagnosis can provide information on the feasibility and safety of trachelectomy. Our aim was to assess the value of an intraoperative SLN diagnosis. METHODS: We retrospectively analyzed the accuracy of intraoperative imprint cytology and frozen-section examination in 201 patients at our institution in whom trachelectomy was planned...
November 15, 2017: Oncology
https://www.readbyqxmd.com/read/29131021/a-novel-color-fluorescence-navigation-system-for-intraoperative-transcutaneous-lymphatic-mapping-and-resection-of-sentinel-lymph-nodes-in-breast-cancer-comparison-with-the-combination-of-gamma-probe-scanning-and-visible-dye-methods
#6
Norihiro Hokimoto, Takeki Sugimoto, Tsutomu Namikawa, Taku Funakoshi, Toyokazu Oki, Maho Ogawa, Hideo Fukuhara, Keiji Inoue, Takayuki Sato, Kazuhiro Hanazaki
BACKGROUND: This study evaluated the clinical efficacy of a novel imaging system (HyperEye Medical System [HEMS]; Mizuho Corp., Tokyo, Japan) that uses the near-infrared (NIR) fluorescence of indocyanine green to analyze sentinel lymph node (SLN) biopsies for the staging of breast cancer. METHODS: This study enrolled 91 patients with histologically confirmed breast cancer that was clinically node negative with a tumor size <3 cm. We compared SLN identification rates between HEMS and conventional methods (gamma probe scanning using a colloidal radioisotope [RI] and a blue dye method) by analyzing the relationships of lymphatic to axillary lesions and SLNs...
November 10, 2017: Oncology
https://www.readbyqxmd.com/read/29080886/patterns-of-relapse-after-definitive-chemoradiotherapy-in-stage-ii-iii-non-t4-esophageal-squamous-cell-carcinoma
#7
Kazuki Sudo, Ken Kato, Hiroki Kuwabara, Yusuke Sasaki, Naoki Takahashi, Hirokazu Shoji, Satoru Iwasa, Yoshitaka Honma, Natsuko T Okita, Atsuo Takashima, Tetsuya Hamaguchi, Yasuhide Yamada, Yoshinori Ito, Jun Itami, Takahiro Fukuda, Kensei Tobinai, Narikazu Boku
PURPOSE: The purpose of this study was to investigate the utility of surveillance after definitive chemoradiotherapy (dCRT) in patients with squamous cell carcinoma. METHODS: Patients who underwent dCRT for stage II/III (excluding T4) esophageal squamous cell carcinoma were analyzed. First failures following complete response were classified into luminal relapse (LR), regional relapse (RR), distant metastasis (DM), new cancer diagnosed by esophagogastroduodenoscopy (NC-E), and new cancer other than NC-E (NC-O)...
October 28, 2017: Oncology
https://www.readbyqxmd.com/read/29065416/bevacizumab-in-combination-with-platinum-based-chemotherapy-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-with-or-without-brain-metastases-a-french-cohort-study-eole
#8
Jaafar Bennouna, Lionel Falchero, Roland Schott, Franck Bonnetain, Mathieu Coudert, Béchir Ben Hadj Yahia, Christos Chouaid
OBJECTIVES: The aim of this study was to describe the characteristics of patients receiving bevacizumab plus first-line metastatic chemotherapy for non-squamous advanced non-small cell lung cancer (aNSCLC), with or without brain metastases, in routine clinical practice. Other objectives were to describe treatment efficacy, modalities of use, and safety. METHODS: For this non-interventional, prospective, national, multicentre study, data were collected every 3 months over 18 months...
October 25, 2017: Oncology
https://www.readbyqxmd.com/read/29045948/impact-of-gastric-cancer-surgery-in-elderly-patients
#9
Tomoyuki Wakahara, Nozomi Ueno, Tetsuo Maeda, Kiyonori Kanemitsu, Takuro Yoshikawa, Shinobu Tsuchida, Akihiro Toyokawa
OBJECTIVES: This study aimed to investigate the validity of gastric cancer surgery in elderly patients. METHODS: A total of 544 patients who underwent elective gastrectomy for gastric cancer were divided into an elderly group (age ≥75 years, n = 171) and a control group (age <75 years, n = 373). The clinicopathological data of the patients were reviewed. RESULTS: The overall morbidity rate (26.3 vs. 16.1%, p = 0.005) and the incidence rate of anastomotic leakage (6...
October 19, 2017: Oncology
https://www.readbyqxmd.com/read/29040974/an-intergroup-randomized-phase-ii-study-of-bevacizumab-or-cetuximab-in-combination-with-gemcitabine-and-in-combination-with-chemoradiation-in-patients-with-resected-pancreatic-carcinoma-a-trial-of-the-ecog-acrin-cancer-research-group-e2204
#10
Jordan D Berlin, Yang Feng, Paul Catalano, James L Abbruzzese, Philip A Philip, Robert R McWilliams, Andrew M Lowy, Al B Benson Iii, A William Blackstock
OBJECTIVES: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS: Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab...
October 18, 2017: Oncology
https://www.readbyqxmd.com/read/29024931/brain-metastases-from-biliary-tract-cancer-a-monocentric-retrospective-analysis-of-450-patients
#11
Giorgio Frega, Ingrid Garajová, Andrea Palloni, Maria Aurelia Barbera, Marco Trossello Pastore, Luca Faccioli, Luca Spinardi, Stefania De Lorenzo, Marta Cubelli, Maria Abbondanza Pantaleo, Guido Biasco, Giovanni Brandi
OBJECTIVE: Brain metastases (BMs) from biliary tract cancer (BTC) are extremely rare. The aim of our study was to report the incidence of BMs in patients with BTC. METHODS: We retrospectively analyzed a series of 450 patients with BTC. Presence of brain lesions was investigated only when symptoms were evident. Cumulative incidence, median overall survival (OS) from detection of BMs, median OS from cancer diagnosis, and median time from cancer diagnosis to detection of BMs were evaluated...
October 13, 2017: Oncology
https://www.readbyqxmd.com/read/29017163/ptis-and-pt1a-ipsilateral-breast-tumor-recurrence-is-associated-with-good-prognosis-after-salvage-surgery
#12
Makoto Ishitobi, Reiko Fukui, Yoko Hashimoto, Nobuyoshi Kittaka, Takahiro Nakayama, Yasuhiro Tamaki
OBJECTIVES: Patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery have a poor prognosis. There is little information regarding the prognostic impact of the tumor size in patients with IBTR. METHODS: A total of 143 patients who had histologically confirmed IBTR without distant metastases and who underwent salvage surgery between 1989 and 2013 in our hospital were included. Distant disease-free survival (DDFS) was calculated according to the invasive tumor size of IBTR...
October 11, 2017: Oncology
https://www.readbyqxmd.com/read/29017161/prognostic-factors-for-survival-in-patients-with-advanced-intrahepatic-cholangiocarcinoma-treated-with-gemcitabine-plus-cisplatin-as-first-line-treatment
#13
Utako Ishimoto, Shunsuke Kondo, Akihiro Ohba, Mitsuhito Sasaki, Yasunari Sakamoto, Chigusa Morizane, Hideki Ueno, Takuji Okusaka
OBJECTIVES: Intrahepatic cholangiocarcinoma (ICC) is a rare type of liver cancer. No clinically useful prognostic factors have been reported for patients with advanced ICC. In the present study, we aimed to evaluate the clinical prognostic factors of patients with advanced ICC receiving gemcitabine plus cisplatin combination therapy (GC) as standard first-line chemotherapy. METHODS: A retrospective analysis was performed of the data of patients with ICC treated at our institution from March 2011 to January 2016...
October 11, 2017: Oncology
https://www.readbyqxmd.com/read/28982109/retrospective-analysis-of-ca19-9-decrease-in-patients-with-metastatic-pancreatic-carcinoma-treated-with-folfirinox-or-gemcitabine-in-a-randomized-phase-iii-study-accord11-prodige4
#14
Marie Robert, Marta Jarlier, Sophie Gourgou, Françoise Desseigne, Marc Ychou, Olivier Bouché, Beata Juzyna, Thierry Conroy, Jaafar Bennouna
OBJECTIVES: Carbohydrate antigen 19-9 (CA19-9) is a sensitive and specific serum marker in pancreatic cancer. Our retrospective analysis aims to evaluate CA19-9 decrease in patients with metastatic pancreatic cancer treated in ACCORD11/PRODIGE4 (FOLFIRINOX vs. gemcitabine). METHODS: A total of 342 patients were treated. CA19-9 was measured at 8 weeks (±2) in 160 patients from a total of 282 with abnormal CA19-9 values at baseline (gemcitabine arm, n = 75; FOLFIRINOX arm, n = 85)...
October 6, 2017: Oncology
https://www.readbyqxmd.com/read/28950265/early-breast-cancer-in-the-elderly-characteristics-therapy-and-long-term-outcome
#15
Omer Gal, Yael Ishai, Aaron Sulkes, Tzipora Shochat, Rinat Yerushalmi
OBJECTIVE: The number of older adults diagnosed with breast cancer is increasing. However, data on breast cancer characteristics, treatment, and survival in elderly women are sparse. METHODS: The database of a tertiary cancer center was searched for all women aged ≥65 years who were diagnosed with early breast cancer in 2004-2007. Patients were divided into 2 age groups: 65-75 years and >75 years. Data on tumor, treatment, and outcome parameters were compared...
September 27, 2017: Oncology
https://www.readbyqxmd.com/read/28946142/short-infusion-trabectedin-in-heavily-pretreated-ovarian-cancer-patients-a-single-institution-experience
#16
Claudia Marchetti, Angela Musella, Alessia Romito, Laura Vertechy, Innocenza Palaia, Violante Di Donato, Serena Boccia, Francesca De Felice, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. METHOD: Trabectedin 0.6 mg/m2 was administered as a 3-h infusion every 10 days on a 21-day cycle. The study population was compared to patients treated with weekly paclitaxel 80 mg/m2 intravenously on days 1, 8, 15, and 22 every 4 weeks. RESULTS: We identified 34 patients previously submitted to at least 3 lines of chemotherapy who received single-agent trabectedin between 2010 and 2015...
September 26, 2017: Oncology
https://www.readbyqxmd.com/read/28930749/efficacy-and-safety-of-capecitabine-irinotecan-gemcitabine-and-bevacizumab-as-second-line-treatment-in-advanced-biliary-tract-cancer-a-phase-ii-study
#17
Finn Ole Larsen, Alice Markussen, Laura V Diness, Dorte Nielsen
OBJECTIVE: Since 2010, gemcitabine and cisplatin have been considered standard first-line treatment in patients with advanced biliary tract cancer. Many centers have replaced cisplatin with oxaliplatin, which seems to obtain similar results. While first-line treatment has been well established, there are no phase III trials supporting second-line treatment, and the phase II trials with chemotherapy do not show any clear benefit. In this study, we investigated the effect of adding bevacizumab to chemotherapy in second-line treatment...
September 21, 2017: Oncology
https://www.readbyqxmd.com/read/28918425/definitive-chemoradiotherapy-for-anal-carcinoma-long-term-results-based-on-consistent-time-to-event-endpoints
#18
Francesca De Felice, Maria Teresa Martinetti, Simone Orelli, Nadia Bulzonetti, Daniela Musio, Vincenzo Tombolini
AIM: To report the long-term results after definitive chemoradiotherapy (CRT) for anal carcinoma, using consistent time-to-event endpoints. METHODS AND MATERIALS: Anal carcinoma patient charts were reviewed. All patients received definitive CRT. Overall survival (OS), local failure-free survival (LFFS), locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS), and anal dysfunction-free survival (ADFS) were estimated. RESULTS: In total, 65 patients were included...
September 16, 2017: Oncology
https://www.readbyqxmd.com/read/28918424/systemic-inflammatory-response-is-a-prognostic-marker-in-hiv-infected-patients-with-hepatocellular-carcinoma
#19
David J Pinato, Marco Merli, Alessia Dalla Pria, Shiraz Jamshaid, Kizzy Parker, Nicole Pagani, Hamid Hasson, Caterina Uberti Foppa, Emanuela Messina, Rohini Sharma, Mark Nelson, Mark Bower
BACKGROUND: Hepatocellular carcinoma (HCC) is increasingly prevalent in people living with HIV. Systemic inflammation is a prognostic factor requiring validation in HIV-associated HCC. AIMS: Using a multi-centre database of consecutive HCC cases, we investigated the prognostic role of a panel of inflammatory markers, including neutrophil to lymphocyte ratio (NLR), using univariate and multivariate survival analyses. RESULTS: Fifty-nine patients with HIV-associated HCC secondary to hepatitis C (69%) or B virus infection (32%) were identified...
September 16, 2017: Oncology
https://www.readbyqxmd.com/read/28910818/protein-expression-of-programmed-death-1-ligand-1-and-her2-in-gastric-carcinoma
#20
Eiji Oki, Shinji Okano, Hiroshi Saeki, Yuichiro Umemoto, Koji Teraishi, Yu Nakaji, Koji Ando, Yoko Zaitsu, Nami Yamashita, Masahiko Sugiyama, Yuichiro Nakashima, Kippei Ohgaki, Yoshinao Oda, Yoshihiko Maehara
OBJECTIVES: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gastric cancer. MATERIALS AND METHODS: We examined formalin-fixed tumor samples from 144 gastric cancer patients with a primary diagnosis of gastric carcinoma. Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients...
September 15, 2017: Oncology
journal
journal
21814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"